Exploring CAR-T Therapy: Discussing Its Introduction and Shared Decision-Making in Myeloma Treatment

Panelists discuss how the patient’s journey with multiple myeloma begins with an initial diagnosis followed by first-line treatments and how this informs the decision to consider chimeric antigen receptor T-cell therapy as a subsequent option in their treatment path.

EP: 1.Navigating the Myeloma Journey: Insights from Diagnosis to First-Line Treatment in Standard-Risk Patient

Now Viewing

EP: 2.Exploring CAR-T Therapy: Discussing Its Introduction and Shared Decision-Making in Myeloma Treatment

Video content above is prompted by the following:

• How did your health care team introduce the possibility of chimeric antigen receptor (CAR) T-cell therapy as an option after your previous lines of therapy?
• What factors were considered when deciding to move to CAR T-cell therapy in your treatment journey?

Recent Videos